APA (7th ed.) Citation

Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., . . . Neoptolemos, J. P. (2014). Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial. Elsevier.

Chicago Style (17th ed.) Citation

Middleton, Gary, et al. Gemcitabine and Capecitabine with or Without Telomerase Peptide Vaccine GV1001 in Patients with Locally Advanced or Metastatic Pancreatic Cancer (TeloVac): An Open-label, Randomised, Phase 3 Trial. Elsevier, 2014.

MLA (9th ed.) Citation

Middleton, Gary, et al. Gemcitabine and Capecitabine with or Without Telomerase Peptide Vaccine GV1001 in Patients with Locally Advanced or Metastatic Pancreatic Cancer (TeloVac): An Open-label, Randomised, Phase 3 Trial. Elsevier, 2014.